CL2009001342A1 - Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c; preparados farmaceuticos que lo contienen; compuesto 11 alfa-hidroxi-15 beta, 16 beta-metilen-androst-4-en-3,17-diona; procedimiento para preparar dicho compuesto que comprende el uso de microorganismos. - Google Patents
Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c; preparados farmaceuticos que lo contienen; compuesto 11 alfa-hidroxi-15 beta, 16 beta-metilen-androst-4-en-3,17-diona; procedimiento para preparar dicho compuesto que comprende el uso de microorganismos.Info
- Publication number
- CL2009001342A1 CL2009001342A1 CL2009001342A CL2009001342A CL2009001342A1 CL 2009001342 A1 CL2009001342 A1 CL 2009001342A1 CL 2009001342 A CL2009001342 A CL 2009001342A CL 2009001342 A CL2009001342 A CL 2009001342A CL 2009001342 A1 CL2009001342 A1 CL 2009001342A1
- Authority
- CL
- Chile
- Prior art keywords
- beta
- compound
- carbolactones
- pregn
- androst
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c; preparados farmacéuticos que lo contienen compuesto 11 alfa-hidroxi-15 beta, 16 beta-metilen-androst-4-en-3,17-diona; procedimiento para preparar dicho compuesto que comprende el uso de microorganismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008026793A DE102008026793A1 (de) | 2008-06-02 | 2008-06-02 | C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009001342A1 true CL2009001342A1 (es) | 2010-05-28 |
Family
ID=41061273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009001342A CL2009001342A1 (es) | 2008-06-02 | 2009-06-02 | Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c; preparados farmaceuticos que lo contienen; compuesto 11 alfa-hidroxi-15 beta, 16 beta-metilen-androst-4-en-3,17-diona; procedimiento para preparar dicho compuesto que comprende el uso de microorganismos. |
Country Status (29)
Country | Link |
---|---|
US (1) | US20110130371A1 (es) |
EP (1) | EP2297177B1 (es) |
JP (1) | JP2012528075A (es) |
KR (1) | KR20110020240A (es) |
CN (1) | CN102046646B (es) |
AR (1) | AR071984A1 (es) |
AU (1) | AU2009254266A1 (es) |
BR (1) | BRPI0913401A2 (es) |
CA (1) | CA2726855A1 (es) |
CL (1) | CL2009001342A1 (es) |
CO (1) | CO6321132A2 (es) |
CR (1) | CR11821A (es) |
DE (1) | DE102008026793A1 (es) |
DO (1) | DOP2010000372A (es) |
EA (1) | EA017570B1 (es) |
EC (1) | ECSP10010652A (es) |
ES (1) | ES2389237T3 (es) |
HK (1) | HK1156954A1 (es) |
HN (1) | HN2010002548A (es) |
IL (1) | IL209371A0 (es) |
MA (1) | MA32321B1 (es) |
MX (1) | MX2010013233A (es) |
NZ (1) | NZ589593A (es) |
PE (1) | PE20100154A1 (es) |
SV (1) | SV2010003748A (es) |
TW (1) | TW201000106A (es) |
UY (1) | UY31859A (es) |
WO (1) | WO2009146811A1 (es) |
ZA (1) | ZA201009097B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012004248A1 (de) | 2010-07-08 | 2012-01-12 | Bayer Pharma Aktiengesellschaft | MIKROBIOLOGISCHES VERFAHREN ZUR HERSTELLUNG VON 11α-HYDROXY-DROSPIRENON |
WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
CN102876582B (zh) * | 2011-07-15 | 2015-01-07 | 复旦大学 | 金龟子绿僵菌突变株及其在甾体化合物羟化反应中的应用 |
WO2015055789A1 (en) * | 2013-10-17 | 2015-04-23 | Bayer Pharma Aktiengesellschaft | INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION |
CN105779555B (zh) * | 2014-12-15 | 2021-02-02 | 天津金耀集团有限公司 | 犁头霉和节杆菌联合发酵制备11β-羟基-1,4-二烯-3,20-二酮甾体化合物 |
CN105779553B (zh) * | 2014-12-15 | 2020-10-27 | 天津金耀集团有限公司 | 新月弯孢霉和节杆菌联合发酵制备11β-羟基-1,4-二烯-3,20-二酮甾体化合物 |
CN104862323B (zh) * | 2015-06-02 | 2018-01-16 | 中国农业科学院生物技术研究所 | 修饰苯二酚类化合物的羟化酶基因 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3092628A (en) * | 1959-05-29 | 1963-06-04 | Merck & Co Inc | Aldosterone antagonists |
US3095412A (en) * | 1961-12-19 | 1963-06-25 | Searle & Co | 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs |
DE1183500B (de) | 1962-10-12 | 1964-12-17 | Schering Ag | Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe |
US3539558A (en) * | 1968-08-09 | 1970-11-10 | Searle & Co | 3 - oxygenated 3 - (9alpha,11beta - dichloro-17beta- hydroxyandrosten - 17alpha-yl)propionic acid gamma-lactones and congeners |
DE2453823C2 (de) * | 1974-11-11 | 1984-08-09 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11β,17α-Dihydroxy-15α,16α-methylen-1,4-pregnadien-3,20-dion |
DE2922500A1 (de) | 1979-05-31 | 1980-12-04 | Schering Ag | 6 beta .7 beta |
US4559332A (en) * | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
HUP0402466A2 (en) * | 2004-11-30 | 2006-07-28 | Richter Gedeon Vegyeszet | Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process |
DE102004063864A1 (de) | 2004-12-30 | 2006-07-13 | Schering Ag | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
DE502005004948D1 (de) * | 2005-07-21 | 2008-09-18 | Bayer Schering Pharma Ag | Verfahren zur Herstellung von 3-Oxo-pregn-4-en-21,17-carbolactonen durch die metallfreie Oxidation von 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanen |
WO2007025780A2 (en) * | 2005-09-02 | 2007-03-08 | Recordati Ireland Limited | Aldosterone receptor antagonists |
DE102006030416A1 (de) | 2006-06-29 | 2008-01-03 | Bayer Schering Pharma Ag | 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate |
ITMI20061802A1 (it) * | 2006-09-22 | 2008-03-23 | Antibioticos Spa | Epossidazione di 17-oxo-15,16-metilen steroidi con ilidi di solfossonio |
-
2008
- 2008-06-02 DE DE102008026793A patent/DE102008026793A1/de not_active Withdrawn
-
2009
- 2009-05-26 KR KR1020107026986A patent/KR20110020240A/ko not_active Application Discontinuation
- 2009-05-26 WO PCT/EP2009/003716 patent/WO2009146811A1/de active Application Filing
- 2009-05-26 CN CN2009801206066A patent/CN102046646B/zh not_active Expired - Fee Related
- 2009-05-26 EA EA201001861A patent/EA017570B1/ru not_active IP Right Cessation
- 2009-05-26 JP JP2011512002A patent/JP2012528075A/ja active Pending
- 2009-05-26 AU AU2009254266A patent/AU2009254266A1/en not_active Abandoned
- 2009-05-26 US US12/995,475 patent/US20110130371A1/en not_active Abandoned
- 2009-05-26 NZ NZ589593A patent/NZ589593A/en not_active IP Right Cessation
- 2009-05-26 EP EP09757194A patent/EP2297177B1/de active Active
- 2009-05-26 ES ES09757194T patent/ES2389237T3/es active Active
- 2009-05-26 MX MX2010013233A patent/MX2010013233A/es active IP Right Grant
- 2009-05-26 CA CA2726855A patent/CA2726855A1/en not_active Abandoned
- 2009-05-26 BR BRPI0913401A patent/BRPI0913401A2/pt not_active IP Right Cessation
- 2009-06-02 UY UY0001031859A patent/UY31859A/es not_active Application Discontinuation
- 2009-06-02 TW TW098118251A patent/TW201000106A/zh unknown
- 2009-06-02 AR ARP090101974A patent/AR071984A1/es unknown
- 2009-06-02 CL CL2009001342A patent/CL2009001342A1/es unknown
- 2009-06-02 PE PE2009000762A patent/PE20100154A1/es not_active Application Discontinuation
-
2010
- 2010-11-17 IL IL209371A patent/IL209371A0/en unknown
- 2010-11-30 MA MA33376A patent/MA32321B1/fr unknown
- 2010-12-02 DO DO2010000372A patent/DOP2010000372A/es unknown
- 2010-12-02 CO CO10152259A patent/CO6321132A2/es active IP Right Grant
- 2010-12-02 HN HN2010002548A patent/HN2010002548A/es unknown
- 2010-12-02 SV SV2010003748A patent/SV2010003748A/es unknown
- 2010-12-02 EC EC2010010652A patent/ECSP10010652A/es unknown
- 2010-12-03 CR CR11821A patent/CR11821A/es not_active Application Discontinuation
- 2010-12-17 ZA ZA2010/09097A patent/ZA201009097B/en unknown
-
2011
- 2011-10-24 HK HK11111415.1A patent/HK1156954A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ECSP10010652A (es) | 2011-01-31 |
TW201000106A (en) | 2010-01-01 |
NZ589593A (en) | 2012-04-27 |
AU2009254266A1 (en) | 2009-12-10 |
EA201001861A1 (ru) | 2011-08-30 |
MA32321B1 (fr) | 2011-05-02 |
CR11821A (es) | 2011-02-04 |
DE102008026793A1 (de) | 2009-12-03 |
CN102046646B (zh) | 2013-03-27 |
US20110130371A1 (en) | 2011-06-02 |
EP2297177A1 (de) | 2011-03-23 |
HK1156954A1 (es) | 2012-06-22 |
JP2012528075A (ja) | 2012-11-12 |
ZA201009097B (en) | 2012-05-01 |
SV2010003748A (es) | 2011-04-06 |
PE20100154A1 (es) | 2010-03-20 |
EA017570B1 (ru) | 2013-01-30 |
IL209371A0 (en) | 2011-01-31 |
MX2010013233A (es) | 2010-12-21 |
CO6321132A2 (es) | 2011-09-20 |
CN102046646A (zh) | 2011-05-04 |
BRPI0913401A2 (pt) | 2015-11-24 |
ES2389237T3 (es) | 2012-10-24 |
KR20110020240A (ko) | 2011-03-02 |
EP2297177B1 (de) | 2012-06-20 |
WO2009146811A1 (de) | 2009-12-10 |
DOP2010000372A (es) | 2010-12-31 |
UY31859A (es) | 2010-01-05 |
AR071984A1 (es) | 2010-07-28 |
CA2726855A1 (en) | 2009-12-10 |
HN2010002548A (es) | 2012-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
BRPI0922364A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
UY30759A1 (es) | Compuestos quimicos | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
HN2010001059A (es) | Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
CL2009001342A1 (es) | Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c; preparados farmaceuticos que lo contienen; compuesto 11 alfa-hidroxi-15 beta, 16 beta-metilen-androst-4-en-3,17-diona; procedimiento para preparar dicho compuesto que comprende el uso de microorganismos. | |
BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
CL2008003041A1 (es) | Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
AR110128A2 (es) | Compuesto del grupo de las 3-(imidazoil)-pirazolo[3,4-b]piridinas, composición farmacéutica que lo comprende y método para preparar el mismo | |
CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
GT201000047A (es) | Mejoras en compuestos organicos o relacionadas con los mismos | |
CL2011001331A1 (es) | Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo. | |
UY31864A (es) | Derivados de urea hetericíclica y métodos de uso de los mismos-332 | |
CL2008001728A1 (es) | Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
CL2008001990A1 (es) | Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer. | |
CL2009001089A1 (es) | Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
AR072425A1 (es) | Uso de nifurtimox para el tratamiento de giardiasis | |
BRPI0821116B8 (pt) | composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo | |
AR072426A1 (es) | Uso de nifurtimox para el tratamiento de enfermedades causadas por tricomonadida |